Search

Displaying results 1131 - 1140 of 10000 in total
  1. Drug

    Mangafodipir

    go.drugbank.com/drugs/DB06796
    ApprovedInvestigationalWithdrawn

    Mangafodipir is a contrast agent used as a diagnostic tool administered intravenously to enhance contrast in magnetic resonance imaging (MRI) of the liver and pancreas. … The contrast agent is present as mangafodipir trisodium marketed under the name Teslascan.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    mRNA-1283

    go.drugbank.com/drugs/DB22668
    ApprovedInvestigational

    2 spike protein, allowing for a more targeted immune response and the use of a significantly smaller amount of mRNA per dose. … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from

  3. Drug

    Somatostatin

    go.drugbank.com/drugs/DB09099
    ApprovedInvestigationalWithdrawn

    well as treat acromegaly [T28]. … [DB00104] is a long-acting analogue of somatostatin that inhibits the release of a number of hormones, and is clinically used to relieve symptoms of uncommon gastroenteropancreatic endocrine tumours, as

    Mixtures: Stilamin - Pws Liq IVCategories: P-glycoprotein substrates, Cytochrome P-450 CYP3A Inhibitors
  4. Drug

    Quaternium-15

    go.drugbank.com/drugs/DB14198
    Approved

    Quaternium-15 is a quaternary ammonium salt used as a surfactant and preservative in many products including cosmetics. … It is an anti-microbial agent by virtue of being a formaldehyde releaser, however this can also cause contact dermatitis, a symptom of an allergic reaction, especially in those with sensitive skin.

  5. Drug

    PA-1050040

    go.drugbank.com/drugs/DB06039
    Experimental

    PA1050040, a second generation HIV-1 maturation inhibitor, is a chemical analog of Bevirimat (BVM). It inhibits virus replication by the same mechanism of action as BVM.

  6. Drug

    Pegulicianine

    go.drugbank.com/drugs/DB18731
    ApprovedInvestigational

    Pegulicianine itself is a prodrug comprising three main fragments, one of which contains a fluorescence quencher that keeps the parent molecule optically inactive. … [L50537] The _in vivo_ enzymatic cleavage of pegulicianine results in two optically active fragments that emit a fluorescent signal that can be detected using a fluorescence imaging device.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    PF-03654746

    go.drugbank.com/drugs/DB12201
    Investigational

    PF-03654746 has been investigated for the treatment of Narcolepsy, Schizophrenia, Tourette's Syndrome, and Excessive Daytime Sleepiness.

  8. Drug

    Ebvaciclib

    go.drugbank.com/drugs/DB18967
    Investigational

    Ebvaciclib is under investigation in clinical trial NCT03519178 (A Study of PF-06873600 in People With Cancer).

  9. Drug

    Mosliciguat

    go.drugbank.com/drugs/DB19425
    Investigational

    Mosliciguat is under investigation in clinical trial NCT06635850 (A Phase 2 Study of Mosliciguat in PH-ILD).

  10. Drug

    CX-052075

    go.drugbank.com/drugs/DB31655
    Approved

    the SARS-CoV-2 spike protein, allowing for a more targeted immune response and the use of a significantly smaller amount of mRNA per dose. … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from